The COVID-19 pandemic drove the swift adoption of decentralized clinical trials (DCTs) models and technology, including telemedicine, home health visits, and direct-to-patient drug delivery. 
There’s no going back. DCTs are now a permanent part of the clinical research, which has implications for every stakeholder in the process. 
Read about the implications of the widespread adoption of DCTs for patients, sponsors, sites, regulators and CROs — and the future of clinical research.